Literature DB >> 18243342

Integration of signals mediated by B-cell receptor, B-cell activating factor of the tumor necrosis factor family (BAFF) and Fas (CD95).

Anikó Hancz1, Zoltán Hérincs, Zsuzsa Neer, Gabriella Sármay, Gábor Koncz.   

Abstract

The survival of the mature resting B cells depends on signaling from B cell receptor (BCR), and a plethora of positive and negative regulators, that maintain cellular homeostasis and ultimately determine cell's fate, i.e., survival or programmed death (apoptosis). Among these regulators we have investigated the B cell activating factor belonging to tumor necrosis factor family (BAFF) and the prototypic death receptor Fas/CD95 mediated signals. We have shown that BAFF inhibits Fas-mediated cell death, however, the BCR-driven survival signals were not strengthened by BAFF. Therefore, we propose that BAFF may function independently of the antigen specificity of BCR, thus may enhance the risk of autoimmune diseases by promoting the survival of bystander B cells in the germinal center.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18243342     DOI: 10.1016/j.imlet.2007.12.009

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  3 in total

1.  Major differences in the responses of primary human leukocyte subsets to IFN-beta.

Authors:  Anette H H van Boxel-Dezaire; Joana A Zula; Yaomin Xu; Richard M Ransohoff; James W Jacobberger; George R Stark
Journal:  J Immunol       Date:  2010-10-18       Impact factor: 5.422

2.  A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling.

Authors:  Joanne M Hildebrand; Zhenghua Luo; Michelle K Manske; Tammy Price-Troska; Steven C Ziesmer; Wai Lin; Bruce S Hostager; Susan L Slager; Thomas E Witzig; Stephen M Ansell; James R Cerhan; Gail A Bishop; Anne J Novak
Journal:  J Exp Med       Date:  2010-11-01       Impact factor: 14.307

3.  Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients.

Authors:  Weiqing Huang; Tam D Quach; Cosmin Dascalu; Zheng Liu; Tungming Leung; Miranda Byrne-Steele; Wenjing Pan; Qunying Yang; Jian Han; Martin Lesser; Thomas L Rothstein; Richard Furie; Meggan Mackay; Cynthia Aranow; Anne Davidson
Journal:  JCI Insight       Date:  2018-09-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.